These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1386418)

  • 1. A dopamine D1 receptor antagonist, SCH 23390, selectively blocks vasopressin release after noxious stimuli in the rat.
    Onaka T; Torigoe H; Yagi K
    Neurosci Lett; 1992 Mar; 136(2):157-60. PubMed ID: 1386418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of naloxone on neuroendocrine responses to fear-related emotional stress.
    Onaka T; Yagi K
    Exp Brain Res; 1990; 81(1):53-8. PubMed ID: 2168320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A benzodiazepine, chlordiazepoxide, blocks vasopressin and oxytocin release after footshocks but not osmotic stimulus in the rat.
    Yagi K; Onaka T
    Neurosci Lett; 1996 Jan; 203(1):49-52. PubMed ID: 8742044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The D1 dopamine receptor antagonist, SCH 23390 reduces locomotor activity and rearing in rats.
    Hoffman DC; Beninger RJ
    Pharmacol Biochem Behav; 1985 Feb; 22(2):341-2. PubMed ID: 2858871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral and intraamygdalar administration of the dopamine D1 receptor antagonist SCH 23390 blocks fear-potentiated startle but not shock reactivity or the shock sensitization of acoustic startle.
    Greba Q; Kokkinidis L
    Behav Neurosci; 2000 Apr; 114(2):262-72. PubMed ID: 10832788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions between emotional stress due to fear and hypovolemic stimuli in the control of vasopressin secretion in rats.
    Onaka T; Yagi K
    Neurosci Lett; 1990 Dec; 120(2):187-90. PubMed ID: 1705680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and behavioral effects of D1 dopamine antagonists.
    Barnett A; Iorio LC; McQuade R; Chipkin RE
    Adv Exp Med Biol; 1988; 235():137-44. PubMed ID: 2976247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine D1-like receptor signalling in the hippocampus and amygdala modulates the acquisition of contextual fear conditioning.
    Heath FC; Jurkus R; Bast T; Pezze MA; Lee JL; Voigt JP; Stevenson CW
    Psychopharmacology (Berl); 2015 Jul; 232(14):2619-29. PubMed ID: 25743759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Raction of dopaminergic and vasopressinergic systems in sleep deprivation in rats].
    Oganesian GA; Romanova IV; Mikhrina AL; Paskarenko NM; Kuzik VV
    Ross Fiziol Zh Im I M Sechenova; 2012 Nov; 98(11):1307-13. PubMed ID: 23431761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amygdaloid D1 dopamine receptor involvement in Pavlovian fear conditioning.
    Guarraci FA; Frohardt RJ; Kapp BS
    Brain Res; 1999 May; 827(1-2):28-40. PubMed ID: 10320690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The D1 dopamine receptor antagonist SCH 23390 increases cocaine self-administration in the rat.
    Koob GF; Le HT; Creese I
    Neurosci Lett; 1987 Aug; 79(3):315-20. PubMed ID: 2958724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of SCH 23390 into the medial prefrontal cortex blocks the expression of MDMA-induced behavioral sensitization in rats: an effect mediated by 5-HT2C receptor stimulation and not by D1 receptor blockade.
    Ramos M; Goñi-Allo B; Aguirre N
    Neuropsychopharmacology; 2005 Dec; 30(12):2180-91. PubMed ID: 15841107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of SCH 39166, a novel dopamine D1 receptor antagonist, on [3H]acetylcholine release in rat striatal slices.
    Tedford CE; Crosby G; Iorio LC; Chipkin RE
    Eur J Pharmacol; 1992 Feb; 211(2):169-76. PubMed ID: 1535318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of SCH-23390 on dopamine D1 receptor occupancy and locomotion produced by intraaccumbens cocaine infusion.
    Neisewander JL; Fuchs RA; O'Dell LE; Khroyan TV
    Synapse; 1998 Oct; 30(2):194-204. PubMed ID: 9723789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sleep during acute dopamine D1 agonist SKF 38393 or D1 antagonist SCH 23390 administration in rats.
    Monti JM; Fernández M; Jantos H
    Neuropsychopharmacology; 1990 Jun; 3(3):153-62. PubMed ID: 2141985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infusion of the dopamine D1 receptor antagonist SCH 23390 into the amygdala blocks fear expression in a potentiated startle paradigm.
    Lamont EW; Kokkinidis L
    Brain Res; 1998 Jun; 795(1-2):128-36. PubMed ID: 9622611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Locomotor activity and a conditioned fear response: correlation with cortical and subcortical binding of the dopamine D1 receptor antagonist.
    Siemiatkowski M; Rokicki D; Członkowska AI; Sienkiewicz-Jarosz H; Bidziński A; Płaźnik A
    Neuroreport; 2000 Dec; 11(18):3953-6. PubMed ID: 11192608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Facilitatory role of central dopamine in the osmotic release of vasopressin.
    Yamaguchi K; Hama H
    Brain Res; 1989 Mar; 481(2):388-91. PubMed ID: 2720392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of both dopamine D1 and D2 receptors necessary for amelioration of conditioned fear stress.
    Kamei H; Kameyama T; Nabeshima T
    Eur J Pharmacol; 1995 Feb; 273(3):229-33. PubMed ID: 7737329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A histaminergic H2-receptor antagonist, ranitidine, blocks the suppressive vasopressin response to fear-related emotional stress in the rat.
    Onaka T; Yagi K
    Neurosci Res; 1992 Nov; 15(3):199-205. PubMed ID: 1362604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.